DBV Technologies | DBVT - 资产



金融业
股票价格
USD
资产
USD 233.72M
现金及等价物
USD 194.17M
流动资产
USD 212.94M
流动负债
USD 58.03M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 168.77M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 727.7M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


资产 更改 日
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amarin USD 645.76M 25.01M 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
DBV Technologies USD 233.72M 123.22M 2025-12
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Galectin Therapeutics USD 27.65M 1.76M 2024-06
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Incyte USD 7.34B 381.14M 2026-03
Insmed USD 2.08B 188.7M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
United Therapeutics USD 6.71B 1.17B 2026-03